241 related articles for article (PubMed ID: 12205067)
1. Comparative in vitro activity of garenoxacin against Chlamydia spp.
Donati M; Pollini GM; Sparacino M; Fortugno MT; Laghi E; Cevenini R
J Antimicrob Chemother; 2002 Sep; 50(3):407-10. PubMed ID: 12205067
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
Donati M; Rodrìguez Fermepin M; Olmo A; D'Apote L; Cevenini R
J Antimicrob Chemother; 1999 Jun; 43(6):825-7. PubMed ID: 10404322
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Hammerschlag MR
Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Miyashita N; Niki Y; Kishimoto T; Nakajima M; Matsushima T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Malay S; Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2002 Feb; 46(2):517-8. PubMed ID: 11796366
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approaches to Chlamydia infections.
Senn L; Hammerschlag MR; Greub G
Expert Opin Pharmacother; 2005 Oct; 6(13):2281-90. PubMed ID: 16218888
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
Roblin PM; Kohlhoff SA; Parker C; Hammerschlag MR
Antimicrob Agents Chemother; 2010 Mar; 54(3):1358-9. PubMed ID: 20038627
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.
Chotikanatis K; Kohlhoff SA; Hammerschlag MR
Antimicrob Agents Chemother; 2014; 58(3):1800-1. PubMed ID: 24366753
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Waites KB; Crabb DM; Bing X; Duffy LB
Antimicrob Agents Chemother; 2003 Jan; 47(1):161-5. PubMed ID: 12499185
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
Kimura M; Kishimoto T; Niki Y; Soejima R
Antimicrob Agents Chemother; 1993 Apr; 37(4):801-3. PubMed ID: 8494377
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
Kohlhoff SA; Roblin PM; Reznik T; Hawser S; Islam K; Hammerschlag MR
Antimicrob Agents Chemother; 2004 May; 48(5):1885-6. PubMed ID: 15105151
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
Samra Z; Rosenberg S; Soffer Y; Dan M
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
Roblin PM; Hammerschlag MR
Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of doxycycline and enrofloxacin against European Chlamydia psittaci strains from turkeys.
Butaye P; Ducatelle R; De Backer P; Vermeersch H; Remon JP; Haesebrouck F
Antimicrob Agents Chemother; 1997 Dec; 41(12):2800-1. PubMed ID: 9420065
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
J Antimicrob Chemother; 1999 Oct; 44(4):549-51. PubMed ID: 10588319
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Kohlhoff SA; Huband MD; Hammerschlag MR
Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.
Smith RP; Baltch AL; Ritz WJ; Carpenter AN; Halse TA; Bopp LH
Antimicrob Agents Chemother; 2004 Jun; 48(6):2081-4. PubMed ID: 15155203
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.
Nakata K; Maeda H; Fujii A; Arakawa S; Umezu K; Kamidono S
Antimicrob Agents Chemother; 1992 Jan; 36(1):188-90. PubMed ID: 1317145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
